Carcinoma of Unknown Primary Site Treated with Carboplatin + Paclitaxel + Bevacizumab + Erlotinib and Its Maintenance Chemotherapy

Publisher： Karger

E-ISSN： 1662-6575|7|2|583-590

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.7, Iss.2, 2014-08, pp. : 583-590

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel/carboplatin with or without belinostat as empiric first‐line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial

By  

CANCER, Vol. 121, Iss. 10, 2015-05 ,pp. : 1654-1661

John Wiley & Sons Inc

Access to resources Recommend Favorite

Paclitaxel plus Carboplatin Chemotherapy for Primary Peritoneal Carcinoma: A Study of 22 Cases and Comparison with Stage III–IV Ovarian Serous Carcinoma

By  

Case Reports in Oncology, Vol. 5, Iss. 1, 2012-04 ,pp. : 173-180

Karger

Access to resources Recommend Favorite

Chemorefractory Rhabdomyosarcoma Treated with Radiotherapy, Bevacizumab, Statins and Surgery and Maintenance with Bevacizumab and Chemotherapy

By  

Oncology Research and Treatment, Vol. 31, Iss. 7, 2008-06 ,pp. : 391-393

Karger

Access to resources Recommend Favorite

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-01 ,pp. : 14-17

Karger

Access to resources Recommend Favorite

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-06 ,pp. : 571-576

Karger

Access to resources Recommend Favorite